The Competition Commission of India has reportedly stepped up scrutiny of the proposed merger between Sun Pharmaceutical Industries and Ranbaxy Laboratories.
The CCI is said to have approached the companies asking they the authority shouldn’t launch an investigation; the regulator also reportedly said the merger would result in significant market strength by one company and could affect the costs of crucial drugs within India.
The CCI issued a show-cause notice to each of the companies, according to unnamed officials at the antitrust watchdog. According to reports, the notices mark the first-ever instance that the CCI has referenced national interest to question a proposed merger.
The $3.2 billion merger will need to secure approval by the CCI, various Indian courts, and the Securities and Exchange Board of India.
Full content: Live Mint
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Canadian Breadmakers Settle Price-Fixing Lawsuit
Jul 25, 2024 by
CPI
EssilorLuxottica Open to Meta as Shareholder, Says CEO Francesco Milleri
Jul 25, 2024 by
CPI
California Supreme Court Upholds Proposition 22, Securing Independent Contractor Status for Uber and Lyft Drivers
Jul 25, 2024 by
CPI
Paramount Global Investor Sues to Block Skydance Media Merger
Jul 25, 2024 by
CPI
Software Vendors Win Class Action Status in Antitrust Case Against CDK Global
Jul 25, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – International Trade & Antitrust
Jul 26, 2024 by
CPI
What is Wrong with the WTO Discipline on Subsidies?
Jul 26, 2024 by
CPI
The Abiding Tension Between Trade Remedy Law and Antitrust
Jul 26, 2024 by
CPI
Trade and Antitrust: An End to Isolationism
Jul 26, 2024 by
CPI
International Trade Law and Domestic Regulation of Generative Artificial Intelligence: Divergent Approaches?
Jul 26, 2024 by
CPI